 |
|
|
| |
Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102)
|
| |
| |
Reported by Jules Levin
59th Annual Meeting of the American Association for the Study of Liver Disease
October 31-November 4, 2008
San Francisco, CA
Oral Presentation # 146
Patrick Marcellin1, Maria Buti2, Zahary Krastev3, Selim Gurel4, Rozalina Balabanska5, Geoff Dusheiko6, Robert Myers7, E Jenny Heathcote8, Jeff Sorbel9, Jane Anderson9, Elsa Mondou9 and Franck Rousseau9
AUTHOR CONCLUSIONS - Week 96
TDF demonstrated durable, potent antiviral activity through Week 96:
-- 99% of patients (On-treatment) on therapy had HBV DNA <400 copies/mL (90% ITT)
No resistance to TDF monotherapy detected up to 2 years
Patients can safely and effectively switch from ADV to TDF treatment:
-- 100% of patients (n-treatment) had HBV DNA <400 copies/mL (89% ITT)
TDF was well tolerated through Week 96
|
| |
|
|
|
|
|
